TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04722978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
Description: Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine combined with carboplatin plus placebo
Description: Standard chemotherapy (gemcitabine and carboplatin) plus placebo
Study: NCT05896176

Intervention type: DIAGNOSTIC_TEST
Intervention: a clinical examination and anamnesis
Description: The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
Study: NCT04757337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 6 x 3-week cycles corresponding to a maximal duration of 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Until progression up to 24 months
Study: NCT06133543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted ICG-guided sentinel lymph node biopsy
Description: The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted ICG-guided sentinel lymph node biopsy
Description: The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
Study: NCT05424809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making model
Description: The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation
Study: NCT05733533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2261 oral tablet
Description: HRS-2261 oral tablet, oral, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to HRS-2261
Description: Matching placebo to HRS-2261, oral, BID
Study: NCT05488353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin for Injection,Penpulimab Injection
Description: After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection.
Study: NCT05619523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developing Inclusive Youth (DIY)
Description: Developing Inclusive Youth (DIY) is a web-based curriculum tool that serves as the intervention program. The animated and narrated tool displays eight peer social exclusion scenarios in a range of familiar everyday social contexts (such as the playground and school). Children enter their responses while watching the scenarios. Responses include making decisions about inclusion and exclusion, evaluating the actions as okay or not okay, attributing feelings to includers, excluders, and excluded characters, and selecting reasons that best match their justification for their decisions and evaluations. The program includes teacher-guided group discussions following use of the tool in which teachers facilitate discussions about children's interpretations of the scenarios, evaluations, reflections regarding their own experiences of exclusion, and solutions. Participants will view and discuss 8 scenarios and engage in a discussion for each one over the course of 8 weeks.
Study: NCT05193396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: hydrocortisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets
Study: NCT05967910

Intervention type: OTHER
Intervention: chronic psychological stress
Description: Chronic psychological stress includes symptoms of anxiety and depression.

Intervention type: OTHER
Intervention: chronic psychological stress
Description: Chronic psychological stress includes symptoms of anxiety and depression.
Study: NCT02036723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
Study: NCT06381284

Intervention type: BEHAVIORAL
Intervention: Social media recruitment
Description: Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment

Intervention type: BEHAVIORAL
Intervention: Self-Assessment
Description: Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups

Intervention type: BEHAVIORAL
Intervention: Follow-up
Description: Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
Study: NCT05992038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteotomy with putty
Description: Synthetic ceramic putty

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional osteotomy
Description: conventional osteotomy
Study: NCT05064800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: A single dose of Dabigatran on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir + Dabigatran
Description: PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir + Dabigatran
Description: Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
Study: NCT04913636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Gel
Description: In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Subjects will perform their regular denture cleaning routine.
Study: NCT05141747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study: NCT04811079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL
Study: NCT05797090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Cardioplegic solution
Description: To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
Study: NCT04811079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL
Study: NCT05098379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Rehabilitation Home Exercise Program
Description: Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences.
Study: NCT06680830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEU-411
Description: NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally-administered matched placebo
Study: NCT04703920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be administered in increasing doses up to 1 mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
Study: NCT06685588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU (fluorouracil)
Description: Topical 5-FU (fluorouracil) pretreatment prior to dovonex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU (fluorouracil)
Description: Topical 5-FU (fluorouracil) pretreatment prior to dovonex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: Calcipotriol pre-treatment prior to PDT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: Calcipotriol pre-treatment prior to PDT
Study: NCT06682247

Intervention type: DRUG
Intervention: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Description: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Study: NCT06685250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study: NCT06235957

Intervention type: OTHER
Group type: OTHER
Intervention: Cast 3 weeks
Description: patients will be treated either in a cast or a brace, patients in group A are treated by cast immobilization for 3 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Brace 1 week
Description: patients will be treated either in a cast or a brace, patients in group B are treated in a brace for 1 week
Study: NCT05389839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wechat program
Description: The experimental group used wechat program to calculate insulin dose to guide insulin treatment .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wechat program
Description: The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
Study: NCT04661319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video editing training
Description: 1. The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~2. Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~3. Select a random experimental group.~4. For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~5. Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video editing training
Description: 1. The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~2. Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~3. Select a random experimental group.~4. For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~5. Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation.
Study: NCT05432557

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: No LA injection
Study: NCT05651087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACUDY
Description: LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
Study: NCT06448156

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac arrest and sudden death
Description: Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac arrest and sudden death
Description: Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac arrest and sudden death
Description: Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac arrest and sudden death
Description: Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated
Study: NCT06025721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Risk Homeless Support
Description: There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking\>medication\>sleep\>physical activity\>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
Study: NCT06292481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brunnstorm movement therapy
Description: this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
Study: NCT06332430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN2109
Description: CAN2109 IT injection (once every 3 weeks)
Study: NCT05353647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
Description: A single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
Study: NCT05919810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral herbal powder supplement
Description: oral herbal powder
Study: NCT06359587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laboratory test overuse (LTO) Bundle
Description: Key Components of the LTO Bundle:~Educational materials, including an online module, clinical decision support tool, provision of lab utilization (Audit and Feedback) reports for healthcare providers.~Patient engagement tools, such as videos and educational infographics. System level implementation tools adapted to the local context, including EMR-based tools and order set changes, etc.
Study: NCT06389084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Together parenting course
Description: parenting course and coaching calls
Study: NCT05884320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given by IV (vein)
Study: NCT05642923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Vitamin B1
Description: Synthetic Vitamin B1 400 mg per day
Study: NCT04906148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advertisement content (explicit vs. implicit)
Description: Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advertisement content (explicit vs. implicit)
Description: Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advertisement content (true vs. misleading)
Description: Participants will be randomly assigned to view an advertisement with either true or misleading messaging content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advertisement content (true vs. misleading)
Description: Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
Study: NCT06243913

Intervention type: PROCEDURE
Intervention: IUI with vitrified sperm from donor:
Description: After signing the informed consent, the clinic's Matching team will assign a donor semen straw based on phenotypic characteristics, blood group, and genetic compatibility (if applicable), with the female partner.~On the day of the Intrauterine Insemination (IUI), the laboratory team will thaw the assigned donor semen straw and post-thaw sperm parameters will be analyzed, including the total number of sperm with progressive motility. Subsequently, the IUI will be performed following the standard protocol.
Study: NCT06136728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine 10 MG [Ampyra]
Description: Dalfampridine (10 mg) every 12 hours for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy (motor relearning for mobility and balance) one-on-one twice per week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine plus physical therapy
Description: Dalfampridine (10 mg) every 12 hours for 6 weeks while simultaneously receiving physical therapy (motor relearning for mobility and balance) one-on-one twice per week.
Study: NCT04939038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization
Description: Depending on the condition of the patients, patients will have either endovascular or surgical revascularization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound care
Description: Standard wound care according to guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: Standard wound care according to guidelines
Study: NCT05159388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-344/S095012
Description: PRS-344/S095012 Monotherapy
Study: NCT04799288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
Study: NCT05439252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Snacking
Description: Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.